Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 17/20 | 0.51 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL282240 | 0.90 | GPR119 (0.60) | GPR119MMP13KMT2AMEN1 | |
| SCHEMBL25315425 | 0.85 | GPR119 (0.54) | GPR119MMP13KMT2AMEN1 | |
| SCHEMBL16415290 | 0.85 | GPR119 (0.54) | GPR119MMP13KMT2AMEN1 | |
| SCHEMBL25313896 | 0.85 | GPR119 (0.54) | GPR119MMP13KMT2AMEN1 | |
| SCHEMBL26654990 | 0.84 | GPR119 (0.56) | GPR119MMP13KMT2AMEN1 | |
| SCHEMBL8651411 | 0.84 | GPR119 (0.67) | GPR119MMP13KMT2AMEN1 | |
| SCHEMBL31683631 | 0.83 | GPR119 (0.67) | GPR119MMP13KMT2AMEN1 | |
| SCHEMBL31746376 | 0.82 | GPR119 (0.68) | GPR119MMP13KMT2AMEN1 | |
| SCHEMBL22032226 | 0.82 | GPR119 (0.68) | GPR119MMP13KMT2AMEN1 | |
| SCHEMBL22284322 | 0.81 | GPR119 (0.54) | GPR119MMP13KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10577344-B2 | Therapeutics targeting truncated adenomatous polyposis coli (APC) proteins | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10577344-B2 | Therapeutics targeting truncated adenomatous polyposis coli (APC) proteins | APC, VHL, TP53 | GPR119 3160/4885MMP13 2440/4885KMT2A 2600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.